31 / 35
Novel dominant EGFR solvent-front mutations in AR to osimertinib
Detection by plasma testing of a 69y old
Caucasian female with AR to osimertinib:
•
L858R (MAF 17.9%)
•
T790M (MAF 18.2%)
•
G796S/R (MAF 14.4%)
•C797S/G (MAF 2.26%)
•L792F/H (MAF 0.35%)
•V802F (MAF 0.36%)
S.-H.I. Ou et al.
disables osimertinib
binding by sterical
interference
Ou et al, Lung Cancer 2017